CROs offering ICH Stability Studies with Vaccine
9 published
9 published CROs match ICH Stability Studies and Vaccine.
Locations in this set include United States, China, India, Netherlands, South Korea, and Australia.
Capabilities that show up most often in this set: Analytical Method Development & Validation, Bioanalysis, Flow Cytometry Services, Immunogenicity Assays (ADA / NAb), and Biomarker Assays.
Matching companies
AllucentAllucent is a full-service CRO specializing in clinical development solutions for small and mid-sized biotech companies.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
BioAgilytixBioanalytical CRO specializing in pharmacokinetics, immunogenicity, biomarkers, and CMC analytics with 30+ years of experience and 1,100+ employees conducting 5M+ tests annually.
Emery PharmaFull-service CRO delivering analytical, bioanalytical, and microbiology services across small molecules, biologics, gene therapy, and botanical drugs from discovery through clinical development.
NorthEast BioLabBioanalytical CRO providing PK/PD, immunogenicity (ADA/nAb), cytokine, and biomarker assays across LC-MS, Meso Scale Discovery, ELISA, and ddPCR platforms. Operates GLP/GCLP-compliant facilities and reports DEA and CT approval for Schedule I–IV bioanalysis.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
ProBioProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/stability-studies/vaccine.md